{"doc_id": "mock:metformin-insulin-rct-2024", "sentence_id": "mock:metformin-insulin-rct-2024:sec:abstract:sent:0", "product_a": "insulin", "product_b": "metformin", "sentence_text": "Metformin combined with insulin improved HbA1c and overall survival in patients with type 2 diabetes and obesity in a randomized phase II trial.", "section": "abstract", "publication_date": "2024-02-15", "count": 1}
{"doc_id": "mock:metformin-insulin-rct-2024", "sentence_id": "mock:metformin-insulin-rct-2024:sec:abstract:sent:1", "product_a": "insulin", "product_b": "metformin", "sentence_text": "The primary endpoint was reduced weight loss versus insulin monotherapy, and metformin's profile was superior.", "section": "abstract", "publication_date": "2024-02-15", "count": 1}
{"doc_id": "mock:insulin-switch-2023", "sentence_id": "mock:insulin-switch-2023:sec:abstract:sent:0", "product_a": "insulin", "product_b": "metformin", "sentence_text": "Patients with type 2 diabetes and cardiovascular disease switched to rapid-acting insulin after Glucophage failed to control blood pressure despite intensive counseling.", "section": "abstract", "publication_date": "2023-11-20", "count": 1}
{"doc_id": "mock:insulin-switch-2023", "sentence_id": "mock:insulin-switch-2023:sec:abstract:sent:1", "product_a": "insulin", "product_b": "metformin", "sentence_text": "The add-on therapy of metformin plus insulin was non-inferior compared to insulin alone for obesity management but hypoglycemia risk increased.", "section": "abstract", "publication_date": "2023-11-20", "count": 1}
{"doc_id": "mock:device-review-2024", "sentence_id": "mock:device-review-2024:sec:summary:sent:0", "product_a": "insulin", "product_b": "metformin", "sentence_text": "A meta-analysis suggested insulin delivered via a connected pen device was better than metformin for rapid fasting control in type 2 diabetes.", "section": "summary", "publication_date": "2024-01-05", "count": 1}
{"doc_id": "mock:device-review-2024", "sentence_id": "mock:device-review-2024:sec:summary:sent:1", "product_a": "insulin", "product_b": "metformin", "sentence_text": "Metformin's formulation was administered via the same device and was similar to insulin in tolerability for obesity and cardiovascular disease cohorts.", "section": "summary", "publication_date": "2024-01-05", "count": 1}
{"doc_id": "mock:phase3b-2022", "sentence_id": "mock:phase3b-2022:sec:results:sent:0", "product_a": "insulin", "product_b": "metformin", "sentence_text": "In a phase 3b clinical trial for type 2 diabetes, insulin versus metformin showed equivalent HbA1c outcomes but inferior body weight reduction.", "section": "results", "publication_date": "2022-08-18", "count": 1}
{"doc_id": "mock:cohort-risk-2021", "sentence_id": "mock:cohort-risk-2021:sec:findings:sent:0", "product_a": "insulin", "product_b": "metformin", "sentence_text": "A cohort study reported that metformin combined with insulin decreased toxicity and improved safety perceptions among patients with type 2 diabetes and obesity.", "section": "findings", "publication_date": "2021-05-30", "count": 1}
{"doc_id": "mock:cohort-risk-2021", "sentence_id": "mock:cohort-risk-2021:sec:findings:sent:1", "product_a": "insulin", "product_b": "metformin", "sentence_text": "Case report data indicated metformin and insulin add-on therapy might reduce serious adverse events in chronic kidney disease yet concerns about fatal hypoglycemia remained for cardiovascular disease patients.", "section": "findings", "publication_date": "2021-05-30", "count": 1}
{"doc_id": "mock:cohort-risk-2021", "sentence_id": "mock:cohort-risk-2021:sec:findings:sent:2", "product_a": "insulin", "product_b": "metformin", "sentence_text": "Clinicians compared insulin pens to metformin tablets and concluded insulin was not inferior to metformin for tolerability in obesity management.", "section": "findings", "publication_date": "2021-05-30", "count": 1}
